Y Combinator Backs Yale Spinout Modeling Human Drug Response with AI To Reduce Preclinical Failure

CellType , a Yale University spinout, has joined Y Combinator’s W26 batch with a platform that combines foundation models of human biology with AI agents designed to run end-to-end AI modeling across discovery and early clinical strategy. The company positions its approach as a response to high preclinical failure rates, arguing that more faithful simulation of human biology could reduce attrition before clinical trials.